Infantile cerebellar retinal degeneration

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Infantile cerebellar retinal degeneration | |
|---|---|
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Cerebellar ataxia, Retinal degeneration, Developmental delay |
| Complications | N/A |
| Onset | Infancy |
| Duration | Chronic |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Genetic testing, MRI, Ophthalmologic examination |
| Differential diagnosis | Other neurodegenerative disorders |
| Prevention | N/A |
| Treatment | Supportive care, Physical therapy, Occupational therapy |
| Medication | N/A |
| Prognosis | Variable, often progressive |
| Frequency | Rare disease |
| Deaths | N/A |
Alternate names[edit]
Infantile cerebellar-retinal degeneration; ICRD
Definition[edit]
Infantile cerebellar retinal degeneration (ICRD) is a genetic condition present from birth (congenital) that involves the brain and eyes.
Cause[edit]
- ICRD is a genetic disorder caused by mutations in the ACO2 gene.
- This gene codes for a protein found in the mitochondria that is involved in the citric acid cycle, which is the process in which energy is created from the breakdown of the foods we eat.
Inheritance[edit]
ICRD is inherited in an autosomal recessive manner. This means that to be affected, a person must have a mutation in both copies of the responsible gene in each cell. There is nothing either parent can do, before or during a pregnancy, to cause a child to have this condition. People with ICRD inherit one mutation from each of their parents. The parents, who each have one mutation, are known as carriers. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:
- 25% chance to be affected
- 50% chance to be an unaffected carrier like each parent
- 25% chance to be unaffected and not a carrier
Signs and symptoms[edit]
The signs and symptoms of ICRD usually begin around 2-6 months of age. The main feature of this condition involve a decline of the ophthalmologic and nervous systems and may include:
- Developmental delay and intellectual disability
- Weakness (hypotonia) of the muscles in the chest and abdomen
- Slow, involuntary movement of certain muscles in the body (athetosis)
- Seizures
- Head bobbing
- Retinal degeneration
- Eye abnormalities such as strabismus and nystagmus
- Failure to thrive (slow or inadequate weight gain)
- Hearing and vision loss
- Absence or loss of reflexes
Diagnosis[edit]
- On brain imaging such as MRI, findings may include worsening cerebellar atrophy as well as agenesis of the corpus callosum.
- Additionally, the head of individuals with ICRD may not grow at the same rate as the rest of the body, so it appears to be getting smaller than the rest of the body (progressive microcephaly).
Treatment[edit]
While there is still no cure for this condition, treatment options will depend on the type and severity of symptoms.
NIH genetic and rare disease info[edit]
Infantile cerebellar retinal degeneration is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Infantile cerebellar retinal degeneration
|
|
This article is a stub You can help WikiMD by registering and expanding it with useful details, internal links, formatting, and categories. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health and wellness encyclopedia. |
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian